文献速递呼吸道感染呼吸危重症与机械通气

碳青霉烯耐药在院内肺炎和呼吸机相关性肺炎中的流行病学与结局:一项回顾性队列研究的新算法分析

A Novel Algorithm to Analyze Epidemiology and Outcomes of Carbapenem Resistance Among Patients With Hospital-Acquired and Ventilator-Associated Pneumonia: A Retrospective Cohort Study.
PubMed 文献 · Chest · 2019-01-24

该回顾性队列研究基于Premier研究数据库(2009-2016年),纳入8,969例符合HAP/VAP标准的成人患者,采用新算法分析革兰阴性病原体碳青霉烯耐药(CR)的流行病学与结局。结果显示11.8%的分离株为CR,CR患者更常见女性、内科入院且合并症负担更高,接受不恰当经验性治疗的比例更高(25.8% vs 10.0%),但调整后死亡率无差异,CR与额外住院费用相关($8,921;95%CI 3,864-13,977)。

要点

  • HAP/VAP患者中碳青霉烯耐药革兰阴性菌分离株占11.8%。
  • CR患者接受不恰当经验性治疗的比例显著高于CS患者(25.8% vs 10.0%)。
  • 碳青霉烯耐药与额外住院费用相关,但不影响调整后死亡率。

核心结论

  • 新算法可识别HAP/VAP中高死亡风险患者,碳青霉烯耐药发生率为12%并与显著额外住院费用相关。

研究设计与样本

  • 回顾性队列研究,基于Premier研究数据库(2009-2016年),纳入8,969例符合HAP/VAP标准的住院成人患者。

主要发现

  • 1,059株(11.8%)为碳青霉烯耐药(CR)革兰阴性菌。
  • CR患者较碳青霉烯敏感(CS)患者更常见女性(41.4% vs 33.2%;P < .001)和内科入院(33.8% vs 27.4%;P < .001)。
  • CR患者合并症负担更高(Charlson合并症指数中位数3 vs 2;P < .001)。
  • 铜绿假单胞菌为总体最常见革兰阴性病原体(24.9%),在CS中占23.5%,在CR中占35.3%仅次于嗜麦芽窄食单胞菌(44.0%)。
  • CR患者接受不恰当经验性治疗的比例高于CS患者(25.8% vs 10.0%;P < .001),且碳青霉烯耐药与额外费用相关($8,921;95%CI 3,864-13,977)。

临床怎么用

  • 对HAP/VAP患者应评估碳青霉烯耐药风险,以优化经验性抗菌治疗选择。

局限性

  • 研究基于行政数据,可能受编码准确性影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Carbapenem resistance is a growing concern. Applying a novel algorithm, we examined epidemiology and outcomes of carbapenem resistance among gram-negative pathogens in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). METHODS: In a retrospective cohort design within the Premier Research database (2009-2016), all hospitalized adult patients with a gram-negative organism in a respiratory or blood culture specimen who fit criteria for HAP/VAP based on International Classification of Diseases, Ninth Revision, Clinical Modification, codes were included in the study. RESULTS: Among 8,969 patients with HAP/VAP, 1,059 isolates (11.8%) were carbapenem-resistant (CR) organisms. Patients with CR organisms were more likely female (41.4% vs 33.2%; P < .001) and medical admissions (33.8% vs 27.4%, P < .001) than those with carbapenem-susceptible (CS) organisms. Patients with carbapenem resistance had higher comorbidity burden than those with carbapenem susceptibility (median [interquartile range] Charlson Comorbidity Index score, 3 [1-4] vs 2 [1-4]; P < .001). Pseudomonas aeruginosa was the most common gram-negative pathogen overall (24.9%) and among CS organisms (23.5%), and was second to Stenotrophomonas maltophilia (44.0%) among CR organisms (35.3%). Acinetobacter baumannii accounted for 11.8% of CR organisms and 2.5% of CS organisms (P < .001). Patients with carbapenem resistance were more likely than those with carbapenem susceptibility to receive inappropriate empiric therapy (25.8% vs 10.0%; P < .001). Carbapenem resistance did not affect adjusted mortality (22.9% CR vs 21.6% CS) or postinfection length of stay (except among survivors of VAP), but it was associated with excess costs ($8,921; 95% CI, 3,864-13,977). CONCLUSIONS: Using administrative data, our novel algorithm identified patients with pneumonia at high risk for death, consistent with HAP/VAP. Among them, carbapenem resistance occurred in 12% of all cases and was associated with substantial excess in hospital costs.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Zilberberg MD, Nathanson BH, Sulham K, et al. A Novel Algorithm to Analyze Epidemiology and Outcomes of Carbapenem Resistance Among Patients With Hospital-Acquired and Ventilator-Associated Pneumonia: A Retrospective Cohort Study. Chest. 2019. PMID: 30685333. doi:10.1016/j.chest.2018.12.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。